[Adjuvant chemotherapy for unresectable locally advanced pancreatic cancer in light of its characteristics].
Taoka
Hiroki
H
HPB Interesting Group, SUZUKA General Hospital.
Hirano
Hitomi
H
Mitsui
Yasushi
Y
Umino
Wataru
W
Nobuoka
Yu
Y
Yamashita
Masako
M
Tanigawa
Kenji
K
Yoshimine
Shyuji
S
Imai
Takazumi
T
Kadowaki
Shigenori
S
Miyashita
Kazumi
K
Ikuma
Hiroki
H
Nakamura
Toshigi
T
Murata
Tetsuya
T
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004176:Dipyridamole / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000093542:Gemcitabine
D003841:Deoxycytidine; D016685:Mitomycin; D004176:Dipyridamole; D002955:Leucovorin; D005472:Fluorouracil; D000093542:Gemcitabine